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Abstract
Objective: Hot flashes are experienced by most midlife women. Emerging data indicate that they may be
associated with endothelial dysfunction. No studies have tested whether hot flashes are associated with endothelial
function using physiologic measures of hot flashes. We tested whether physiologically assessed hot flashes were
associated with poorer endothelial function. We also considered whether age modified associations.
Methods: Two hundred seventy-two nonsmoking women reporting either daily hot flashes or no hot flashes,
aged 40 to 60 years, and free of clinical cardiovascular disease, underwent ambulatory physiologic hot flash and
diary hot flash monitoring; a blood draw; and ultrasound measurement of brachial artery flow-mediated dilation to
assess endothelial function. Associations between hot flashes and flow-mediated dilation were tested in linear
regression models controlling for lumen diameter, demographics, cardiovascular disease risk factors, and estradiol.
Results: In multivariable models incorporating cardiovascular disease risk factors, significant interactions by age
(P< 0.05) indicated that among the younger tertile of women in the sample (age 40-53 years), the presence of hot
flashes (beta [standard error]¼2.07 [0.79], P¼ 0.01), andmore frequent physiologic hot flashes (for each hot flash:
beta [standard error]¼0.10 [0.05], P¼ 0.03, multivariable) were associated with lower flow-mediated dilation.
Associations were not accounted for by estradiol. Associations were not observed among the older women (age 54-60
years) or for self-reported hot flash frequency, severity, or bother. Among the younger women, hot flashes explained
more variance in flow-mediated dilation than standard cardiovascular disease risk factors or estradiol.
Conclusions: Among youngermidlife women, frequent hot flasheswere associatedwith poorer endothelial function
and may provide information about women’s vascular status beyond cardiovascular disease risk factors and estradiol.
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C
ardiovascular disease (CVD) is the leading cause of
death among women.1 As women typically manifest
with clinical CVD postmenopausally,2 there has
been a longstanding interest in the role of the menopause
transition and its correlates in thedevelopmentofCVDinwomen.
The focus of this work has largely been on the hormonal changes
of menopause, including declining levels of the ovarian estrogen
estradiol (E2). However, recent data have considered other
menopause-related factors in theCVDrisk amongmidlifewomen.
Hot flashes are the hallmark symptom of the menopause
transition. They are reported by 70% of women,3 and for a
third of women, they are frequent or severe.3,4 Newer data
indicate that hot flashes often start earlier than previously
thought, during the late reproductive years,5 and persist for a
decade or more.6,7 Whereas hot flashes are well-established to
impact a woman’s quality of life, emerging work also links
hot flashes to indicators of CVD risk.
The vascular endothelium, the single cell layer lining the
vessel, is critical to multiple aspects of vascular health and
function, and endothelial injury and dysfunction is an initiat-
ing event in atherosclerosis.8-10 The endothelium has long
been shown to be sensitive to reproductive factors in women,
including reproductive hormones such as E2,
11 and also to
many standard CVD risk factors.12,13 Newer data have begun
to link the menopausal symptom of hot flashes to markers of
poorer endothelial function.9,10,14
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However, the existing literature on hot flashes and endo-
thelial function has key limitations. Most existing work has
employed brief, retrospective assessments subject to many
biases,15,16 including memory biases and other psychological
factors impacting symptom reporting, which themselves are
associated with poorer endothelial function.17 More advanced
physiologic measures of hot flashes18 and prospective assess-
ment self-report measures of hot flashes completed at the time
of the hot flash (rather than recalled at the end of the day)19 do
exist and should be employed to address these questions.
Further, the endothelium is well-known to be sensitive to E2,
yet the E2 assays employed in the existing work have limited
sensitivity at the low levels observed among menopausal
women.20 Finally, there has been little consideration of
factors that may modify hot flash-endothelial associations.
The timing of hot flashes can vary dramatically across
women, with some indication that early-occurring hot flashes
may be those most relevant to CVD risk.14,21 Similar to
relations between a range of female reproductive factors
(eg, hormone therapy, hot flashes) and markers of CVD risk
in women,21,22 any modifying role of chronologic or ovarian
aging in these associations requires careful consideration.
We tested the associations between rigorously and prospec-
tively assessed hot flashes and endothelial function as
assessed by brachial artery flow-mediated dilation (FMD),
a well-validated and widely used index of endothelial function
(lower FMD indicating poorer function).23-26 We considered
the role of CVD risk factors and endogenous E2 concentra-
tions measured via state-of-the-art methods20 in these asso-
ciations. Finally, we considered a priori how age or
menopause stage may modify hot flash-FMD associations.
METHODS
We recruited 304 late perimenopausal (2-12 months amen-
orrhea) and postmenopausal (12 months amenorrhea)27
nonsmoking women aged 40 to 60 years from the community
via advertisements, mailings, and online message boards. By
design, half of the women reported daily hot flashes or night
sweats (‘‘flashers’’), and half reported no hot flashes or night
sweats in the past 3 months (‘‘nonflashers’’). Exclusion
criteria included hysterectomy and/or bilateral oophorec-
tomy; history of heart disease, stroke, arrhythmia, gyneco-
logical cancer, pheochromocytoma, pancreatic tumor, kidney
failure, seizures, Parkinson’s disease, Raynaud’s phenome-
non; current pregnancy; or having used the following med-
ications in the past 3 months: oral/transdermal estrogen or
progesterone (hormone therapy, hormonal contraceptives,
hormone cream/patch/ring, hormone-eluting intrauterine
device), selective estrogen receptor modulators, selective
serotonin reuptake inhibitors, serotonin norepinephrine reup-
take inhibitors, gabapentin, insulin, beta blockers, calcium
channel blockers, alpha-2 adrenergic agonists, or other anti-
arrhythmic agents. Also excluded were women who had
undergone endometrial ablation (preventing menopause
staging), endarterectomy, or lymph node removal, or who
were undergoing chemotherapy, hemodialysis, or peritoneal
dialysis. Of the 304 women, 32 were excluded due to missing
FMD data. An additional four women were excluded from
expanded models due to missing data for Homeostatic Model
Assessment (HOMA, n¼ 2) and low-density lipoprotein cho-
lesterol (LDL-C, n¼ 2). Excluded women did not differ on
any study variables than included women. Thus, 272 women
were included in primary models and 268 women in
expanded models.
Participants underwent physical measurements, ambula-
tory hot flash monitoring, a blood draw, and a carotid artery
ultrasound. All study procedures were reviewed and approved
by the University of Pittsburgh Institutional Review Board,
and all participants provided written, informed consent.
Height and weight were measured via a fixed stadiometer
and a calibrated balance beam scale, and body mass index
calculated (kg/m2). Seated blood pressure (BP) was measured
via a Dinamap device after 10-min rest. Medical and repro-
ductive history was assessed by standard instruments. Meno-
pause status was obtained from reported menstrual bleeding
patterns.27 Parity was classified by the total reported number
of live births. Use of medications (eg, antihypertensives, lipid-
lowering medications, diabetes, inhaled beta agonists) was
reported and considered as covariates. Depressive symptoms
were assessed by the Center for Epidemiologic Studies
Depression scale,28 anxiety via the State-Trait Anxiety Inven-
tory,29 and sleep quality via the Pittsburgh Sleep Quality
Index.30 Leisure-time physical activity was assessed via the
International Physical Activity Questionnaire.31
All women completed ambulatory hot flash monitoring
with an electronic hot flash diary (3 days), wrist actigraph (3
days), and a physiologic hot flash monitor (24 hours). The
physiologic hot flash monitor, the VU-AMS (VU University
Amsterdam, the Netherlands),32,33 is a portable ambulatory
monitor that quantifies hot flashes via sternal skin conduc-
tance, a validated measure of hot flashes.18,34 An electronic
hot flash diary (Palm Z22) was completed at the time of a
waking subjectively experienced hot flash, where women
reported the occurrence, severity, and bother of each waking
hot flash.19 Women also pressed event mark buttons on the
VU-AMS monitor and actigraph when experiencing a hot
flash, providing date and time-stamped hot flash reports.
Participants wore the VU-AMS monitor for 24 hours, after
which time they removed it and stored it in a provided case.
For the remaining 2 days, participants reported their hot
flashes via diary (self-reported occurrence, severity, bother)
and actigraph (self-reported occurrence). After monitoring,
hot flash data were downloaded, reviewed, and scored via UFI
software (DPSv3.7; Morro Bay, CA) according to standard,
validated methods18,34,35 that have established reliability in
the present laboratory (k¼ 0.86).36 The frequency of physio-
logic or self-reported hot flashes was calculated as the number
of hot flashes divided by monitoring time; women not show-
ing or reporting hot flashes, respectively, were assigned a zero
value. Average severity and bother over the monitoring period
was calculated over diary entries. In addition to reporting on
their hot flashes as they occurred, on the first day of the
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protocol, women completed a questionnaire similar to that
used in epidemiologic investigations,3,16 whereby they were
asked to report on the frequency (number of days with hot
flashes and number of hot flashes per day), severity (1¼ not at
all to 4¼ severe), and bother (1¼ not at all to 4¼ a lot)
associated with hot flashes as recalled over the prior 2 weeks.
After an overnight fast, FMD was measured after
10minutes of supine rest by high-resolution B-mode ultra-
sound imaging of the right brachial artery, 2 to 10 cm proxi-
mal to the antecubital crease, by trained sonographers using a
standardized protocol. Images were obtained at rest (baseline)
and after 5minutes of forearm blood flow occlusion (post-
deflation) with a pneumatic tourniquet set to 50mmHg above
the participant’s systolic BP. For baseline diameters, digitized
images were captured on the R wave for 20 seconds. Imme-
diately after deflation, images were captured on the R wave
for 3minutes. The arterial diameter was measured as the
distance between the anterior and posterior arterial wall
media-adventitia interfaces using edge-detection software.
All images for this study were read by a single trained reader
using the Brachial Analysis System (MIA, University of
Iowa) software.37 The reading software allows continuous
tracking of the brachial artery diameter across these images so
that the peak change in diameter can be accurately deter-
mined. FMD was calculated as the maximum percentage of
change in arterial diameter, relative to baseline. This meth-
odology at this laboratory has shown reproducibility (intra-
class correlation coefficient¼ 0.70-0.72).17
Phlebotomy was performed after a 12-hour overnight fast.
E2 was assessed via liquid chromatography-tandem mass
spectrometry, the gold standard method to measure E2 at
the low levels of the postmenopause (lower limit of quanti-
tation¼ 2.5pg/mL; lower limit of detection¼ 1.0 pg/mL).38
Glucose, high-density lipoprotein cholesterol (HDL-C), and
triglycerides were measured enzymatically (Vital Diagnos-
tics, Lincoln, RI). Total cholesterol was determined enzymat-
ically and LDL-C calculated using the Friedewald formula.39
Insulin was measured via radioimmunoassay. HOMA, reflect-
ing insulin resistance, was calculated.40 C-reactive protein
was measured using a high-sensitivity reagent set (Beckman
Coulter, Brea, CA) and interleukin (IL)-6 with an R&D
Systems (Minneapolis, MN) via high-sensitivity ELISA.
For data analyses, E2, HOMA, triglycerides, C-reactive
protein, and IL-6 values were natural log-transformed and
leisure time physical activity square root transformed for
analysis. Hot flash rates were calculated as the number of
hot flashes/monitoring time. Differences between participants
by included/excluded status were tested using linear regres-
sion, Wilcoxon rank sum, and chi-square tests. Associations
between hot flash status or hot flash frequency and brachial
artery measures (FMD, lumen diameter) were tested in linear
regression models. Covariates were entered as factors associ-
ated with FMD in the present study at P less than 0.20:
baseline lumen diameter, age, race/ethnicity, leisure time
physical activity, state anxiety, parity, beta agonist medica-
tions (model 1), and next addition of CVD and demographic
risk factors of body mass index, systolic BP, triglycerides,
LDL-C, HOMA, education, and BP-lowering, lipid-lowering,
and diabetes medications (model 2). E2 was added to model 2
in a separate step. All variables were treated as continuous
variables with the exception of race/ethnicity (white/non-
white), education (< or college), and medication use
(yes/no). To avoid issues of collinearity, BP and lipid vari-
ables with the strongest associations with the outcome were
selected for inclusion in model 2. Interactions were tested by
cross product terms in multivariable models, with age and
time since the last reported menstrual period considered as
continuous variables. Significant interactions were probed in
stratified models, with age tertiled according to the sample
distribution for illustration. R2 values were derived from
linear regression models. Secondary models included addi-
tional covariates added to model 2 (sleep quality, depressive
symptoms, IL-6, C-reactive protein). Residual analysis and
diagnostic plots were conducted to verify model assumptions.
Analyses were performed with SAS v9.2 (SAS Institute, Cary,
NC). Models were two-sided at a 0.05.
RESULTS
Participants were on average 54 years old, white, college
educated, and postmenopausal (Table 1). Although being on
average overweight, the average CVD risk factor profile was
relatively favorable. Participants showed an average of six
physiologic hot flashes/24 h on physiologic monitoring and
reported an average of two hot flashes (waking hours).
Physiologically monitored and self-reported hot flash fre-
quency during waking hours were moderately to highly corre-
lated (r¼ 0.69, P< 0.0001), consistent with other work.41
Flow-mediated dilatation did not differ between ‘‘flashers’’
(M [SE]¼ 7.37 [4.18]) and ‘‘nonflashers’’ (M [SD]¼ 7.60
[3.91], P¼ 0.32; model 2 covariates). Further, neither the
frequency of physiologic hot flashes (B [SE]¼0.01 [0.03],
P¼ 0.70) nor self-reported hot flashes (b [SE]¼0.13 [0.08],
P¼ 0.09,model 2 covariates)was significantly related toFMD.
However, age significantly modified the association
between hot flash status and FMD (P value interaction:
P¼ 0.02, model 1 covariates; P¼ 0.03, model 2 covariates),
such that among the younger tertile of women (age 40-53
years), ‘‘flashers’’ had significantly lower FMD than ‘‘non-
flashers’’ (Table 2). Age also moderated the association
between physiologically monitored hot flash frequency and
FMD (P value interaction: P¼ 0.03, model 1 covariates;
P¼ 0.035, model 2 covariates), such that a greater frequency
of physiologic hot flashes was associated with poorer FMD
among the younger women (Table 2, Fig. 1). CVD risk factors
and other model 2 covariates did not account for these asso-
ciations. In contrast, we did not observe significant age inter-
actions for self-reported hot flash frequency in relation to FMD.
Notably, among the younger tertile of women, hot flash status
accounted for more variance in FMD than all other covariates,
with the exception of baseline lumen diameter (Table 3).
We next considered the role of E2. E2 was not significantly
related to FMD (b [SE]¼ 0.01 [0.28], P¼ 0.96, multivariable).
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E2 did not reduce themagnitude or significance of hot flash-age
interactions with FMD, nor did it reduce the association
between hot flashes and FMD among the youngest tertile of
women in multivariable models (data not shown).
We conducted several additional analyses. First, we con-
sidered the variance accounted for by physiologic hot flash
frequency instead of hot flash status among the younger
women in multivariable models; physiologic hot flash
frequency accounted for 4.1% of the variance, greater than
that of all standard CVD risk factors (see Supplemental
Table 1, http://links.lww.com/MENO/A220). Second, we
considered interactions between hot flashes and menopause
stage, race/ethnicity (white/non-white), or time since last
menstrual period in relation to FMD. There were no signifi-
cant interactions for race/ethnicity or the time since the last
menstrual period. However, there was some evidence of an
TABLE 1. Sample characteristics (N¼ 272)
Total sample Age 53 Age 53.1-56 Age >56
Age, y, mean (SD)a 54.1 (3.9) 50.2 (2.8) 55.1 (0.8) 58.4 (1.0)
Race/ethnicity, n (%)
White 198 (72.8) 73 (67.0) 63 (74.1) 62 (79.5)
African American 59 (21.7) 30 (27.5) 18 (21.2) 11 (14.1)
Other (Asian, Hispanic, biracial) 15 (5.5) 6 (5.5) 4 (4.7) 5 (6.4)
Education, n (%)
High school, some college, vocational 114 (41.9) 47 (43.1) 38 (44.7) 29 (37.2)
College graduate 79 (29.0) 33 (30.3) 23 (27.1) 23 (29.5)
Postgraduate 79 (29.0) 29 (26.6) 24 (28.2) 26 (33.3)
Parity, median (IQR) 2.0 (1.0, 3.0) 2.0 (1.0, 3.0) 2.0 (0.0, 2.0) 2.0 (1.0, 3.0)
State anxiety, mean (SD)b 32.2 (9.9) 33.5 (10.3) 31.8 (9.6) 30.8 (9.4)
Depressive symptoms, median (IQR)b 5.5 (2.0, 11.0) 6.0 (3.0, 11.0) 6.0 (2.0, 12.0) 4.5 (1.0, 10.0)
Leisure time physical activity, median (IQR)b 396.0 (0, 1386.0) 330.0 (0.0, 1470.0) 495.0 (66.0, 1097.0) 346.5 (0.0, 1050.0)
Body mass index, mean (SD) 29.0 (6.8) 29.1 (6.7) 28.9 (8.0) 29.0 (5.6)
Systolic blood pressure, mm Hg, mean (SD)a 119.5 (14.4) 117.0 (13.2) 118.4 (12.0) 124.1 (17.1)
Diastolic blood pressure, mmHg, mean (SD) 69.9 (9.0) 70.8 (9.6) 69.2 (8.2) 69.5 (9.2)
Menopause stage, n (%)a
Perimenopausal 44 (16.2) 36 (33.0) 7 (8.2) 1 (1.3)
Postmenopausal 228 (83.8) 73 (67.0) 78 (91.8) 77 (98.7)
High density lipoprotein cholesterol, mg/dL, mean (SD) 62.7 (14.7) 60.7 (15.1) 64.4 (15.5) 63.8 (13.1)
Low density lipoprotein cholesterol, mg/dL, mean (SD) 131.0 (33.8) 126.0 (30.7) 134.7 (31.7) 134.1 (39.2)
Triglycerides, mg/dL, median (IQR) 95.5 (71.5, 130.0) 94.0 (74.0, 128.0) 96.0 (74.0, 126.0) 100.5 (70.0, 143.0)
Homeostatic model assessment, median (IQR) 2.7 (1.7, 3.2) 2.1 (1.6, 2.9) 2.1 (1.6, 3.4) 2.4 (1.8, 3.1)
Estradiol, pg/mL, median (IQR)a 5.0 (2.0, 10.1) 5.4 (2.9, 16.0) 4.8 (2.0, 8.0) 4.0 (2.0, 8.0)
Medications, n (%)
Lipid-loweringa 36 (13.2) 7 (6.4) 12 (14.1) 17 (21.8)
Blood pressure-lowering 45 (16.5) 16 (14.7) 13 (15.3) 16 (20.5)
Diabetes medication 10 (3.7) 3 (2.8) 2 (2.4) 5 (6.4)
Beta-agonists 14 (5.2) 7 (6.4) 3 (3.5) 4 (5.1)
Hot flash status, n (%)a
Yes 136 (50) 41 (37.6) 40 (47.1) 55 (70.5)
No 136 (50) 68 (62.4) 45 (52.9) 23 (29.5)
Physiologically detected hot flashes, 24 hr, mean (SD)a 9 (9) 9 (9) 10 (9) 7 (9)
Self-reported hot flashes, waking, mean (SD)a 2 (3) 3 (3) 2 (3) 1 (2)
Flow mediated dilation, %, mean (SD) 7.4 (4.3) 7.6 (3.9) 7.4 (4.3) 7.1 (4.0)
Baseline lumen diameter, mm, mean (SD) 3.5 (0.5) 3.5 (0.5) 3.4 (0.5) 3.5 (0.5)
IQR, interquartile range; SD, standard deviation.
aDiffers by age status (P< 0.05).
bState anxiety assessed by Spielberger State-Trait Anxiety Inventory, sample range: 20 to 63; depressive symptoms assessed by Center for Epidemiologic
Studies Scale, sample range: 0 to 51; leisure time physical activity assessed by International Physical Activity Questionnaire, sample range: 0 to 6,399.
TABLE 2. Relation between hot flashes and FMD by age tertile
Model 1 Model 2
Age 53 Age 54-56 Age 57 Age 53 Age 54-56 Age 57
b (SE) b (SE) b (SE) b (SE) b (SE) b (SE)
Hot flash status (yes/no) 1.90 (0.72)a 1.06 (0.89) 0.38 (0.94) 2.15 (0.79)a 0.67 (0.96) 0.44 (1.04)
Frequency of physiologic hot flashesb 0.08 (0.04)c 0.07 (0.05) 0.02 (0.05) 0.10 (0.05)c 0.05 (0.06) 0.03 (0.05)
Model 1: Age, baseline lumen diameter, race/ethnicity, state anxiety, parity, physical activity, beta agonist medication.
Model 2: Model 1 plus education, SBP, BMI, HOMA, LDL, triglycerides, lipid-lowering medication, blood pressure-lowering medication, diabetes
medication.
All variables were treated as continuous variables with the exception of race/ethnicity (white or non-white), education (< or college), and medication
use (yes/no for each medication).
BMI, body mass index; FMD, flow-mediated dilation; HOMA, Homeostatic Model Assessment; LDL, low-density lipoprotein; SBP, systolic blood pressure.
aP< 0.01.
bBeta refers to increase in FMD accompanied by each additional physiologic hot flash.
cP< 0.05.
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interaction between physiologic hot flash frequency and
menopause stage (interaction P value: P¼ 0.048, model 1
covariates; P¼ 0.06, model 2 covariates), such that associa-
tions between physiologic hot flashes and FMD were stron-
gest among the perimenopausal women (b [SE]¼0.16
[0.06], P¼ 0.02), controlling for age and other model 1
covariates. Findings in perimenopausal women persisted with
adjustment for model 2 covariates (b [SE]¼0.18 [0.08],
P¼ 0.03). Third, we considered physiologically detected hot
flashes during sleep versus wake hours among the younger
women. The most pronounced associations between hot
flashes and FMD were observed for waking (b [SE]¼0.12
0.12 [0.05], P¼ 0.01) rather than sleep hot flashes (b
[SE]¼0.09 [0.14], P¼ 0.51, model 1 covariates). Fourth,
neither diary-reported severity nor bother associated with
hot flashes was associated with FMD, nor did they show
interactions by age in relation to FMD. We also examined
questionnaire-reported hot flashes (frequency, severity,
bother, past 2 weeks) in relation to FMD. None of these
indices was significantly related to FMD for the sample as a
whole. However, there was some indication of an interaction
between hot flash bother and age in relation to FMD
(P¼ 0.058, model 2 covariates); in age-stratified analyses,
greater hot flash-related bother was associated with lower
FMD among the younger tertile (age 53 years, b [SE]¼
0.90 [0.41], P¼ 0.03, model 2 covariates), but not the older
tertiles of women (age 54-56 years, b [SE]¼0.06, P¼ 0.90;
age >56 years, b [SE]¼0.56 [0.64], P¼ 0.38, model 2
covariates). Finally, we considered additional covariates of
inflammatory markers, depressive symptoms, and sleep qual-
ity, but these markers did not explain any of the observed
associations (data not shown).
DISCUSSION
This study was the first to test relations between physio-
logically assessed hot flashes and endothelial function as
assessed by brachial artery FMD. We found that both the
reported presence of hot flashes and more frequent physio-
logically assessed hot flashes were associated with lower
FMD among younger midlife women. Associations between
hot flashes and FMD were not observed among the older
women in the sample. Observed associations were not
explained by a range of potentially confounding or explana-
tory factors, including standard CVD risk factors or endoge-
nous E2. Thus, for younger midlife women, hot flashes appear
to be accompanied by poorer endothelial function.
The endothelium is the single cell layer lining the vessel
that is critical to multiple aspects of vascular health.8 Repro-
ductive hormonal factors such as E2 have long been shown to
be associated with endothelial function.11 The present study
shows that menopausal hot flashes are associated with poorer
endothelial function independent of E2 among younger
women only. With its rigorous quantification of hot flashes,
CVD risk factors, and E2, this study is the most definitive on
the topic to date. Notably, impairment in endothelial function
is an initiating event in the atherosclerotic process,42 and
thereby frequent hot flashes may mark emerging vascular
dysfunction among early midlife women.
Hot flash-FMD associations showed pronounced effect
modification by age, and to a lesser extent menopause stage.
Effects were primarily observed among the younger and
perimenopausal women, and not among the older women
in the sample. Notably, hot flashes were long thought to begin
in the few years before the final menstrual period, yet newer
data indicate that a substantial portion of women have hot
flashes very early in midlife.5 These hot flashes may mark
FIG. 1. Flow-mediated dilation (FMD) and physiologic hot flashes by
age. Covariates: age, race, baseline diameter, physical activity, parity,
state anxiety, body mass index, systolic BP, education, HOMA, LDL,
triglycerides, medications (beta agonist, lipid-lowering, BP-lowering,
diabetes medications). All variables were treated as continuous variables
with the exception of race/ethnicity (white or non-white), education (< or
college), and medication use (yes/no for each medication). HOMA,
Homeostatic Model Assessment; LDL, low-density lipoprotein;
BP, blood pressure.
TABLE 3. Percent of variance (R2) in FMD explained by each
variable in multivariable models among women aged 53 years or less
Variable R2
Age 1.2
Baseline lumen diameter 6.4
Race 1.9
Education 0.30
Body mass index 0.20
Systolic blood pressure 0.01
Low-density lipoprotein cholesterol 0.30
Triglycerides 1.6
Homeostatic Model Assessment 0.10
State anxiety 4.2
Parity 0.10
Physical activity 2.6
Medications
Lipid-lowering 2.4
Blood pressure-lowering 0.20
Diabetes 0.20
Beta agonist 4.7
Hot flash status (yes/no) 5.6
All variables were treated as continuous variables with the exception of
race/ethnicity (white or non-white), education (< or college), and
medication use (yes/no for each medication).
FMD, flow-mediated dilation.
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poorer vascular health, as in the present study, the FMD of the
youngest women with hot flashes was similar to the FMD of
women in the oldest tertile. Large prospective cohort studies
(eg, Study of Women’s Health Across the Nation) similarly
indicate that it is the women who have hot flashes early in the
transition who have the highest subclinical atherosclerosis
even when controlling for CVD risk factors.21 In the Wom-
en’s Ischemia Syndrome Evaluation study, women who
recalled earlier onset of their hot flashes had lower FMD.14
The reason for these patterns of findings is not immediately
apparent, yet it is possible that effects for hot flashes are
observed in younger women, whereas aging effects on endo-
thelial function predominate in older women. Notably, there is
some evidence that the predictive value of FMD for CVD is
stronger in younger populations.23 Thus, different CVD
markers may show different temporal relations to hot flashes,
progressing from endothelial dysfunction to atherosclerosis to
clinical CVD events. Further supporting this interpretation are
findings indicating that hot flashes may be linked to clinical
CVD events primarily in older women.43 Notably, effect
modification by age is a frequent observation for relations
between reproductive hormonal factors (eg, hormone therapy)
and CVD risk in women.22,44,45
The mechanisms that may link hot flashes to poorer
endothelial function require elucidation. Hot flashes are con-
ceptualized as thermoregulatory events occurring in the con-
text of the altered thermoregulation observed during the
menopause transition, possibly secondary to endogenous E2
withdrawal. A large literature shows that exogenous estrogen
administration improves endothelial function,11 particularly
for younger midlife women.45 Endogenous E2, measured via
state-of-the-art liquid chromatography-tandem mass spec-
trometry methods, was not related to FMD here, suggesting
a potential differing vascular physiology of endogenous E2
versus exogenous estrogen administration. Further, traditional
or novel CVD risk factors linked to hot flashes46-48 did not
explain observed associations. Notably, hot flashes may be
associated with greater reactivity of the microvasculature, a
response often mediated by the sympathetic nervous system.49
Emerging work also links the hypothalamic pituitary adrenal
axis to hot flashes,50 which is also associated with poorer
vascular health.51 These pathways should be considered in
future work.
Several additional findings deserve mention. Somewhat
stronger associations were observed for waking versus sleep
hot flashes. The reason for this pattern of findings is not
immediately apparent. However, this finding is broadly con-
sistent with our prior work,9,52,53 potentially suggesting dif-
fering underlying physiologies or correlates of these two
events. Prospectively reported frequency, severity, and bother
associated with hot flashes were not associated with FMD.
However, there was some indication that the general bother
associated with hot flashes, as recalled over the prior 2 weeks,
was associated with poorer endothelial function among the
younger women in the sample, paralleling findings for phys-
iologic hot flash frequency. Memory and reporting effects
associated with recalled hot flashes are well-established,15
particularly for self-reported bother,16 and should be kept in
mind when interpreting these findings. However, it is possible
that the overall perceived bother associated with hot flashes
captures an aspect of the frequent physiologic hot flashes not
captured by prospective self-report.
There are several limitations to this work. The majority of
women in the sample were postmenopausal, and early peri-
menopausal women were not included; future work should
consider associations among these women. Brachial artery
FMD is a validated measure indexing vascular responses
largely mediated by the endothelium, but is not as direct a
measure as more invasive measures.26 Moreover, participants
were recruited to be reporting either no hot flashes in the past
3 months or daily hot flashes, and thereby associations among
women reporting infrequent hot flashes could not be assessed.
Larger studies with longitudinal outcomes should be con-
ducted to further confirm findings. Finally, the sample
included relatively few racial/ethnic minority women, partic-
ularly Hispanic and Asian women. Future work should exam-
ine these women.
This study had significant strengths. It provides the most
rigorous test to date of relations between hot flashes and
brachial artery FMD. FMD is a widely accepted and widely
utilized noninvasive marker of endothelial function that cor-
relates with later clinical events.23-26 Hot flashes were pro-
spectively assessed by self-report and physiologic means,
reducing the impact of memory and reporting. Highly symp-
tomatic women were included and characterized. A range of
possible mechanisms and confounders were rigorously
assessed and considered here, including CVD risk factors,
E2, and also psychological factors associated with symptom
reporting.54
CONCLUSIONS
In sum, the present investigation found that among non-
smoking younger midlife women (age 40-53 years), hot
flashes were associated with markers of poor endothelial
function. Associations were not observed for the older women
in the sample (age 54-60 years). All associations were inde-
pendent of CVD risk factors and of endogenous E2 concen-
trations. These findings point to the potential value in
considering the role of not only hormones, but also hot
flashes, in the cardiovascular changes that occur early in
the menopause transition,55 while also underscoring the
potential role that the endothelium may play in the physiology
of early hot flashes. With further replication and extension of
this work, these findings may indicate that among early
midlife women, frequent hot flashes may signal emerging
vascular dysfunction.
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